Sea Pharmaceuticals LLC has announced it is advancing two new orally administered neurotherapeutic molecules for neurological disorders. SPM-0404 and SPM-0606 are biologically active as dual AMPA receptor (AMPAR) and kainate receptor (KAINR) antagonists.
NRG Therapeutics Ltd., has nominated NRG-5051 as its first development candidate, and secured a $5 million grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its preclinical development of as a disease-modifying treatment for Parkinson’s disease.
Mabylon AG has been awarded three grants totaling more than CHF1.3 million (US$1.5 million) from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.
NRG Therapeutics Ltd. has been awarded a grant from Target ALS Foundation to support its discovery program for a treatment for amyotrophic lateral sclerosis (ALS).
Acurastem Inc. has secured $4 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to facilitate the development of its UNC13A program toward clinical trials for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
A new brain-computer interface (BCI) developed at UC Davis Health is able to translate brain signals into speech with up to 97% accuracy – the most accurate system of its kind.
Nervgen Pharma Corp. has outlined its plans to develop its new drug candidate, NVG-300, with a focus on three initial indications: ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).
Shanghai Henlius Biotech Inc. has announced preclinical data showing that its small-molecule drug HLX-99 exhibited antineurodegenerative activities in multiple models, warranting further development.
